Results 61 to 70 of about 20,250 (180)

Combined MEK1/2 and Autophagy Inhibition Suppresses Tumor Growth via STING‐Mediated Type I Interferon Response in iCCA

Cancer Science, EarlyView.
Through bioinformatic analyses, iCCA cell models, and in vivo xenograft experiments, we show that autophagy inhibition sensitizes iCCA to MEK1/2 blockade by enhancing STING‐dependent type I interferon signaling. These findings support combined MEK1/2 and autophagy inhibition as a promising therapeutic strategy for iCCA. ABSTRACT The RAF–MEK–ERK pathway
Chengqiang Sun, Zheng Gao, Enfu Dong, Liangxia Ding, Shanru Feng, Jiafeng Chen, Pascal Kwangwari, Yinghong Shi, Weiren Liu, Xin Zhang, Ao Huang, Jian Zhou, Sheng Wang, Jia Fan, Xiutao Fu, ZhenBin Ding   +15 more
wiley   +1 more source

A Three‐Dimensional Culture–Drug Sensitivity Test Predicts MDM2 Inhibitor–Sensitivity in SMARCB1/INI1‐Deficient Tumors

Cancer Science, EarlyView.
This study aimed to determine whether personalized selection of effective drugs for SMARCB1/INI1‐deficient tumors is feasible using in vitro drug sensitivity profiling. Drug sensitivity was assessed using a short‐term collagen gel–embedded three‐dimensional drug sensitivity test (3D‐DST) in tumors derived from SMARCB1/INI1‐deficient tumor cell line ...
Hiroaki Goto, Chiyoko Nishime, Takashi Ohtsu, Mieko Ito, Maiko Sagisaka, Takuya Naruto, Norihiko Kitagawa, Mio Tanaka, Masakatsu Yanagimachi, Yukihiko Hiroshima, Junko Takita, Yasuhide Hayashi, Yohei Miyagi   +12 more
wiley   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He, Shaymaa Hegazy, Phyu P. Aung, Priyadharsini Nagarajan, Fiorinda Muhaj, Adrienne N. Choksi, Ana M. Ciurea, Kelly C. Nelson, Doina Ivan, Carlos A. Torres‐ Cabala, Victor G. Prieto, Jonathan L. Curry   +11 more
wiley   +1 more source

Combination of AURKA inhibitor and MEK inhibitor strongly enhances G1 arrest and induces synergistic antitumor effect on KRAS or BRAF mutant colon cancer cells

Biochemistry and Biophysics Reports
In colorectal cancer, RAS and BRAF are major mutation points in the RAS-MAPK signaling pathway. These gene mutations are known to be important causes of resistance to anti-EGFR antibody therapies.
Masashi Sato, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Kuniaki Fukuda, Kiichiro Tsuchiya   +4 more
doaj   +1 more source

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer

Neoplasia: An International Journal for Oncology Research, 2014
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and epidermal growth factor receptor (EGFR) family signaling are drivers of tumorigenesis in pancreatic ductal adenocarcinoma (PDAC).
James M. Lindberg, Timothy E. Newhook, Sara J. Adair, Dustin M. Walters, Alison J. Kim, Edward B. Stelow, J. Thomas Parsons, Todd W. Bauer   +7 more
doaj   +1 more source

Building a precision therapeutics program at a tertiary care children's hospital

Pediatric Investigation, EarlyView.
Luke Hamilton, Heidi Trinkman, Diana Carrasco, Kaitlin Smith, Kelly Vallance, Alejandra Dominguez, Danielle Miller, Megan Gibbs, Anish Ray   +8 more
wiley   +1 more source

Darier disease—A review highlighting new insights from the Darier Disease International Task Force

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review provides a global, clinically focused overview of DD, detailing cutaneous and extracutaneous manifestations, disease classification and severity scoring. It emphasizes early recognition, multidisciplinary management and practical guidance for dermatologists to apply evidence‐based care in diverse skin phototypes. Abstract Darier disease (DD)
Sofia Labbouz, Alain Hovnanian, Grace Xiong, Dedee Frances Murrell, Simon M. Mueller, Khaled Ezzedine, Nessa Aghazadeh Mohandesi, Ahmed Salem Aldhaheri, Nissim Asayag, Eulalia Baselga, Chen Nadler, Keith Choate, Chia‐Yu Chu, John Robert Edminister, Emmanuella Guenova, Melis Gönülal, Antoni Gostynski, Ankan Gupta, Lalit Kumar Gupta, Juliette Mazereeuw‐Hautier, Wolfram Hoetzenecker, Peter Itin, Marek Jankowski, Akiharu Kubo, Haur Yueh Lee, Julia Scott Lehman, Anfisa Lepekhova, Márta Medvecz, Jemima E. Mellerio, Verena Moosbrugger‐Martinz, Amy S. Paller, Dóra Plázár, Amadeu José Rodrigues Queiróz, Josep Riera‐Monroig, Ralph Rosa, Matthias Schmuth, Maella Severino Freire, Itzhak Shabat, Jonathan Shapiro, Cory L. Simpson, Diego Soto‐García, Alexander J. Stratigos, Gianluca Abel Tadini, Takuya Takeichi, Kaushal K. Verma, Jakob D. Wikström, Alexander Zink, Michael Ziv, Alexander Navarini, Roni Pircha Dodiuk‐Gad   +49 more
wiley   +1 more source

Pediatric Langerhans Cell Histiocytosis Presenting With Bilateral Parotid Gland Swelling and Cystic Lung Disease: A Case Report and Literature Review

Pediatric Dermatology, EarlyView.
ABSTRACT Langerhans cell histiocytosis (LCH) is a neoplastic process originating from immature myeloid precursor cells. In this report, we describe a case of a 17‐month‐old with scaling of the scalp and swelling of the bilateral parotid glands who developed acute respiratory distress.
Aretha On, Robert Smith, Robert Duffy, Maria B. Queenan, Melinda Jen   +4 more
wiley   +1 more source

Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond

International Journal of Cancer, Volume 159, Issue 7, Page 1780-1787, 1 October 2026.
Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia, Søren Kjær Petersen, Louise M. Guldbrandt, Troels H. Borch, Christina H. Ruhlmann, Rasmus Blechingberg Friis, Adam A. Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Eva Ellebaek, Marco Donia   +11 more
wiley   +1 more source